CSTB and CTSD

Number of citations of the paper that reports this interaction (PubMedID 3261170)
6

Data Source:
HPRD (in vitro)

		CSTB	CTSD
Description		cystatin B	cathepsin D
Image
GO Annotations	Cellular Component	Extracellular Region Extracellular Space Nucleus Nucleolus Cytoplasm Cytosol Secretory Granule Lumen Collagen-containing Extracellular Matrix Extracellular Exosome Tertiary Granule Lumen Ficolin-1-rich Granule Lumen	Extracellular Region Extracellular Space Lysosome Lysosomal Membrane Endosome Membrane Specific Granule Lumen Melanosome Lysosomal Lumen Membrane Raft Collagen-containing Extracellular Matrix Extracellular Exosome Tertiary Granule Lumen Ficolin-1-rich Granule Lumen
	Molecular Function	Protease Binding RNA Binding Endopeptidase Inhibitor Activity Cysteine-type Endopeptidase Inhibitor Activity	Aspartic-type Endopeptidase Activity Protein Binding Peptidase Activity Aspartic-type Peptidase Activity
	Biological Process	Adult Locomotory Behavior Negative Regulation Of Peptidase Activity Negative Regulation Of Endopeptidase Activity Neutrophil Degranulation Negative Regulation Of Proteolysis	Proteolysis Antigen Processing And Presentation Of Exogenous Peptide Antigen Via MHC Class II Protein Catabolic Process Collagen Catabolic Process Lipoprotein Catabolic Process Positive Regulation Of Apoptotic Process Positive Regulation Of Cysteine-type Endopeptidase Activity Involved In Apoptotic Process Neutrophil Degranulation Regulation Of Establishment Of Protein Localization
Pathways		Neutrophil degranulation	Collagen degradation Metabolism of Angiotensinogen to Angiotensins MHC class II antigen presentation Neutrophil degranulation Estrogen-dependent gene expression
Drugs		Cupric Chloride	Insulin Human Insulin Pork S-Methylcysteine 1h-Benoximidazole-2-Carboxylic Acid N-Aminoethylmorpholine 5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE
Diseases		Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)	Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10) Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
GWAS		Blood protein levels in cardiovascular risk ( 28369058)	Blood protein levels ( 30072576) Blood protein levels in cardiovascular risk ( 28369058) Logical memory (delayed recall) in mild cognitive impairment ( 29274321)
Interacting Genes		9 interacting genes: COL6A1 CST3 CTSB CTSD CTSH CTSL ECT2 RAD21 SPRY2	23 interacting genes: APP BGLAP CCL21 CD4 CST3 CSTB CTSB FN1 HSPB2 IGF2R IGFBP3 IGFBP4 INS MAPK1 MAPT NLGN3 PSAP SERPINA4 SHBG SLC2A4 SNCA SPRED2 TG
Entrez ID		1476	1509
HPRD ID		03091	00291
Ensembl ID		ENSG00000160213	ENSG00000117984
Uniprot IDs		P04080 Q76LA1	P07339 V9HWI3
PDB IDs		1STF 2OCT 4N6V	1LYA 1LYB 1LYW 4OBZ 4OC6 4OD9
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?